Rhythm Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Rhythm Pharmaceuticals' es David Meeker , nombrado en Jul 2020, tiene una permanencia de 3.75 años. compensación anual total es $3.33M, compuesta por 19.6% salario y 80.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.29% de las acciones de la empresa, por valor de $6.81M. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 4.8 años, respectivamente.
Información clave
David Meeker
Chief Executive Officer (CEO)
US$7.2m
Compensación total
| Porcentaje del salario del CEO | 9.7% |
| Permanencia del CEO | 3.8yrs |
| Participación del CEO | 0.3% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 4.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 09
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon
May 05Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22
Mar 03Rhythm Pharmaceuticals: Action Too Specific
Feb 23Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price
Jan 08We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely
Nov 03We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate
Jul 23Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing
Jun 17Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates
May 05Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans
Apr 01An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued
Dec 15We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully
Oct 24Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Oct 10Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours
Sep 14Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS
Sep 06Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts
Aug 08Rhythm Pharmaceuticals Q2 2022 Earnings Preview
Aug 01Rhythm Pharma gains as NICE recommends obesity drug
Jul 18Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
Jun 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$274m |
| Dec 31 2023 | US$7m | US$705k | -US$185m |
| Sep 30 2023 | n/a | n/a | -US$186m |
| Jun 30 2023 | n/a | n/a | -US$182m |
| Mar 31 2023 | n/a | n/a | -US$181m |
| Dec 31 2022 | US$3m | US$652k | -US$181m |
| Sep 30 2022 | n/a | n/a | -US$181m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$166m |
| Dec 31 2021 | US$6m | US$630k | -US$70m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$60m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$15m | US$262k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$146m |
| Dec 31 2019 | US$287k | n/a | -US$141m |
| Sep 30 2019 | n/a | n/a | -US$133m |
| Jun 30 2019 | n/a | n/a | -US$115m |
| Mar 31 2019 | n/a | n/a | -US$87m |
| Dec 31 2018 | US$282k | n/a | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$47m |
| Dec 31 2017 | US$268k | n/a | -US$38m |
Compensación vs. Mercado: La compensación total ($USD7.23M) de David está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.66M).
Compensación vs. Ingresos: La compensación de David ha aumentado mientras la empresa no es rentable.
CEO
David Meeker (69 yo)
3.8yrs
Permanencia
US$7,230,457
Compensación
Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 3.8yrs | US$7.23m | 0.29% $ 6.8m | |
| CFO & Treasurer | 6.8yrs | US$2.31m | 0.16% $ 3.8m | |
| Chief Technical Officer | 3.8yrs | US$1.74m | 0.000050% $ 1.2k | |
| Executive VP & Head of International | 3.6yrs | US$1.74m | 0.057% $ 1.4m | |
| Executive VP & Head of North America | 3.5yrs | US$2.11m | 0.011% $ 268.2k | |
| Corporate Controller | 1.2yrs | sin datos | 0.0013% $ 31.0k | |
| Head of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
| Senior VP & General Counsel | 3.5yrs | sin datos | sin datos | |
| Vice President of Sales & Marketing | no data | sin datos | sin datos | |
| Chief Human Resources Officer | 2.8yrs | sin datos | 0.049% $ 1.2m | |
| Senior VP & Head of Strategy | 2.3yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 1.7yrs | sin datos | sin datos |
3.5yrs
Permanencia media
51yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RYTM se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 8.5yrs | US$7.23m | 0.29% $ 6.8m | |
| Corporate Controller | 1.2yrs | sin datos | 0.0013% $ 31.0k | |
| Independent Director | 4.9yrs | US$283.77k | 0% $ 0 | |
| Independent Director | 8.5yrs | US$308.77k | 0% $ 0 | |
| Lead Independent Director | 11.2yrs | US$328.77k | 0.0095% $ 225.8k | |
| Independent Director | 3.4yrs | US$298.77k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.8yrs | US$301.27k | 0% $ 0 |
4.9yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de RYTM se considera experimentada (4.8 años de antigüedad promedio).